---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-113966"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:54:53.728462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# uniQure Q3 net loss $47.9M; DSMB recommends resuming higher-dose AMT-130 enrollment

## Summary
- Net loss $47.9M ($1.02/share) vs $36.5M ($0.79) in Q3 2021; revenue $1.4M down from $2.0M.
- Cash $440.3M as of Sep 30, 2022; expected to fund operations into H1 2025.
- DSMB recommends resuming higher-dose AMT-130 enrollment in European Phase Ib/II after SUSARs resolved.
- BLA for etranacogene dezaparvovec under FDA priority review; EMA issued GMP certificate.
- IND-enabling studies initiated for AMT-260 (epilepsy) and AMT-191 (Fabry); submissions expected 2023.

## SEC filing metadata
- accession: 0001104659-22-113966
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/0001104659-22-113966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/tm2229521d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-113966
- JSON: https://secwatch.observer/filing/0001104659-22-113966.json
- Plain text: https://secwatch.observer/filing/0001104659-22-113966.txt

## Key facts
- Earnings Releases
  uniQure N.V. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 2, 2022, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and highlighting company progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465922113966/0001104659-22-113966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.